Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENSET - GENXY -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (165)	3/2/2001 7:00:56 PM
From: Mike McFarland	Respond to of 200

Assessing the Cost-Effectiveness of Pharmacogenomics aaps.org Just some interesting reading. When Pernet spoke in January at ChaseHQ, he made it sound as though the CEA thing did not count for much genxy.com ...and that Genset would be doing some sort of a deal in the low cost genotyping area. I've fumbled around, but have not got any closer to figuring out the riddle. If anybody has a clue, step right up, or I'll just keep talking to myself, mucking up the thread;-) My guess is that some sort of a merger is in the works, the change in strategy, management shake up, exodus, and the "Genset Pharma" initiative may or may not fit into all this--who can say what is smoke screen and what is real mismanagement and fumbling.